These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 741533)
1. Cellular cytotoxicity in transitional cell carcinoma of the human urinary bladder - a summary. Perlmann P; Troye M; Pape G; Blomgren H; Johansson B Urol Res; 1978; 6(4):207-9. PubMed ID: 741533 [TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures. Troye M; Vilien M; Pape GR; Perlmann P Int J Cancer; 1980 Jan; 25(1):33-43. PubMed ID: 7399743 [TBL] [Abstract][Full Text] [Related]
3. A 51chromium isotope release assay for detecting cytotoxicity to human bladder carcinoma. O'Toole C Int J Cancer; 1977 Mar; 19(3):324-31. PubMed ID: 844912 [TBL] [Abstract][Full Text] [Related]
4. Cellular cytotoxicity in vitro in transitional cell carcinoma of the human urinary bladder: 51Cr-release assay. Troye M; Perlmann P; Larsson A; Blomgren H; Johansson B Int J Cancer; 1977 Aug; 20(2):188-98. PubMed ID: 892930 [No Abstract] [Full Text] [Related]
5. Disease-related lymphocyte cytotoxicity in rats bearing transitional cell carcinoma of bladder. Effect of immunomodulators. Moroz C; Madgar I; Twig S; Lindner A; Many M Int J Cancer; 1982 Jun; 29(6):667-72. PubMed ID: 6980847 [TBL] [Abstract][Full Text] [Related]
6. Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls. Troye M; Hansson Y; Paulie S; Perlmann P; Blomgren H; Johansson B Int J Cancer; 1980 Jan; 25(1):45-51. PubMed ID: 7399744 [TBL] [Abstract][Full Text] [Related]
7. Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24. Catalona WJ; Oldham RK; Djeu JY; Herberman RB; Cannon GB Surg Forum; 1975; 26():122-4. PubMed ID: 56048 [No Abstract] [Full Text] [Related]
8. A follow-up study of urinary bladder patients tested for tumour-related lymphocyte-mediated cytotoxicity. Larsson A; Näslund I; Troye M Cancer Immunol Immunother; 1982; 14(2):82-5. PubMed ID: 6965230 [TBL] [Abstract][Full Text] [Related]
9. Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder. Bubeník J Int Urol Nephrol; 1975; 7(4):297-302. PubMed ID: 1107249 [TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immune reactions against tumor cells in patients with urinary bladder carcinoma. Correlation between direct and antibody-dependent cell-mediated cytotoxicity. Hansson Y; Paulie S; Larsson A; Lundblad ML; Perlmann P; Näslund I Cancer Immunol Immunother; 1983; 16(1):23-9. PubMed ID: 6556949 [TBL] [Abstract][Full Text] [Related]
11. Tumor-associated and spontaneous lymphocyte-mediated cytotoxicity against cell lines derived from human urothelium. Vilien M Dan Med Bull; 1985 Aug; 32(4):199-218. PubMed ID: 3899526 [No Abstract] [Full Text] [Related]
12. Cellular immunity to transitional cell carcinoma of the urinary bladder. III. Effects of hydrostatic pressure therapy. O'Toole C; Helmstein K; Perlmann P; Moberger G Int J Cancer; 1975 Sep; 16(3):413-26. PubMed ID: 1176202 [TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxicity studies in bladder and renal cell cancer. Elhilali MM; Nayak SK Urology; 1976 May; 7(5):488-91. PubMed ID: 1274005 [TBL] [Abstract][Full Text] [Related]
14. Classification of the bladder cancer patient based on in vitro measurements of the immune response. Lange PH; Hakala TR; Fraley EE Cancer Res; 1977 Aug; 37(8 Pt 2):2885-90. PubMed ID: 326395 [TBL] [Abstract][Full Text] [Related]
15. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. Mizutani Y; Yoshida O J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797 [TBL] [Abstract][Full Text] [Related]
16. Immunologic evaluation of human bladder cancer: in vitro studies. Elhilali MM; Nayak SK Cancer; 1975 Feb; 35(2):419-31. PubMed ID: 1111918 [TBL] [Abstract][Full Text] [Related]
17. Membrane-associated antigens on tumor cells from transitional-cell carcinoma of the human urinary bladder. I. Immunological characterization by xenogeneic antisera. Schneider MU; Troye M; Paulie S; Perlmann P Int J Cancer; 1980 Aug; 26(2):185-92. PubMed ID: 7203712 [TBL] [Abstract][Full Text] [Related]
18. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. Mizutani Y; Nio Y; Yoshida O J Urol; 1992 Feb; 147(2):505-10. PubMed ID: 1732632 [TBL] [Abstract][Full Text] [Related]
19. Lymphocyte antibody interaction in cytotoxicity against human transitional cell carcinoma. Hakala TR; Lange PH; Castro AE; Elliott AY; Fraley EE J Urol; 1975 May; 113(5):663-7. PubMed ID: 1168732 [TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]